Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that an investigator initiated study combining the diabetes vaccine Diamyd® and GABA in children with new onset type 1 diabetes has been approved by the US Food and Drug Administration. Diamyd Medical and University of Alabama at Birmingham has entered a Clinical Trial Agreement regarding the study, which will be conducted at Children’s of Alabama in Birmingham, USA. The combination has shown promising results in preclinical studies. Principal Investigator for the new GABA and Diamyd® combination study is Kenneth McCormick, MD, Professor of Pediatrics at University of Alabama at Birmingham. “We envisage that administering GABA to those with new onset type 1 diabetes may preserve residual insulin production, suppress glucagon release, and decrease inflammation in and around the pancreas,” says Dr. McCormick. “Combining this with Diamyd®, which aims to specifically halt the autoimmune attack may synergistically help save endogenous insulin production, improve glycemic control and decrease the risk of hypoglycemia and long-term complications.” The clinical study is a three-arm, double-blind, placebo-controlled trial and will enroll a total of 75 newly diagnosed type 1 diabetes children and adolescents between 4 and 18 years of age. Patients will be assigned to one of three treatment groups to receive either: a) two injections of Diamyd® plus GABA for 12 months; b) GABA only; or c) placebo. Patients will be followed for a total of 12 months, after which the effect on preserving endogenous insulin production will be analyzed. Diamyd Medical has in-licensed exclusive rights for therapeutic use of GABA (gamma-aminobutyric acid) for the treatment of diabetes and other inflammation -related conditions. Combination therapy with GABA and GAD65, which is the active substance in Diamyd®, has been shown to act synergistically and prolong the survival of transplanted insulin producing beta cells in type 1 diabetes animal models (Tian et al. PLoS One 2011; 6(9):e25337). The Diamyd® diabetes vaccine is easily administered in any clinical setting and has been used in studies with more than 1000 diabetes patients. In a European Phase III study with children and adolescents recently diagnosed with type 1 diabetes, Diamyd® showed an overall 16% efficacy (p=0.10) versus placebo in preserving endogenous insulin secretion. The aim of combing treatment with Diamyd® and GABA is to test if this effect can be enhanced. About type 1 diabetes Type 1 diabetes is an autoimmune disease where the immune system attacks the patients’ own insulin producing beta cells. By analyzing markers in the blood it is possible to identify persons in whom this autoimmune process is ongoing, although has not yet caused clinical symptoms of diabetes. When type 1 diabetes presents with clinical symptoms, patients must be treated daily, for the rest of their lives, with insulin to sustain life. The importance of finding a cure is high for the world’s health care systems and the wellbeing of patients. The annual market for an easy to use, successful therapeutic is estimated to several billion dollars. About Diamyd Medical Diamyd Medical is dedicated to fight type 1 diabetes and to work towards a cure for the disease. Diamyd Medical’s current projects include development of combination regimens for arresting the successive destruction of insulin producing beta cells using the Company’s GAD65-based diabetes vaccine Diamyd®, such as Diamyd® + Vitamin D with or without an anti-inflammatory compound; and Diamyd® combined with GABA, for which Diamyd Medical licenses exclusive intellectual rights from the University of California in Los Angeles (UCLA). Diamyd Medical has further acquired 46% of the stem cell company Cellaviva AB that is establishing a Swedish commercial bank for private family saving of stem cells in umbilical cord blood and other sources of stem cells. Stem cells are required for Personalized Regenerative Medicine (PRM), for example to restore beta cell mass in diabetes patients where autoimmunity has been arrested. Remium Nordic AB is the Company’s Certified Adviser. For further information, please contact: Anders Essen-Möller, Chairman Diamyd Medical AB Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com
Pioneering study combining the diabetes vaccine Diamyd®
Top 10 Most Recent News Articles
Stitch AI Targets Banking’s Hardest Automation Gap
The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...
Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand
A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...
Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves
A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...
Continue Reading
Rochester Truck Crashes Demand a Different Liability Map
An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...
Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets
Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...
Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test
A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...
Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth
Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...
Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence
Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...
Continue Reading
Parents Hand Kids Devices Years Before They Intended
A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...
Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further
Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...
Continue ReadingTop 5 Most Recently Viewed Articles
Liberty Media Corp Achieves Milestone with Stock Surge
Liberty Media Corporation Reaches New 52-Week High Liberty Media Corp (FWONA), a significant player in the media and entertainment sectors, has recently achieved a landmark 52-week high in its stock price, soaring to $75.71. This impressive rise has brought attention to the company's strong market performance, reflecting a substantial gain of 31.03% over the past year....
Continue Reading
Telegram's Pavel Durov Responds to Content Moderation Criticism
Pavel Durov Addresses Concerns Over Telegram's Moderation Pavel Durov, the CEO of Telegram, has recently addressed the growing concerns about the platform’s moderation practices. In a message to his large audience of over 12 million subscribers, Durov pledged that the company would take steps to respond to the criticism regarding how Telegram handles content management....
Continue Reading
FiscalNote Expands Its Reach with New Public Sector Customers
FiscalNote Expands Its Reach with New Public Sector Customers FiscalNote Holdings, Inc. (NYSE: NOTE), renowned for its AI-driven enterprise SaaS technologies, has recently made headlines by securing a myriad of new agreements across the U.S. public sector. These contracts span the federal government's three branches, showcasing the Company's celebrated suite of products...
Continue Reading
Bluejay Diagnostics to Showcase Symphony IL-6 Findings at SAEM
Exciting Announcement from Bluejay Diagnostics Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has recently made a remarkable announcement that will resonate within the medical community. This innovative healthcare company has had an abstract accepted for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting. This significant event is scheduled to take...
Continue Reading
Clean Maine Carbon Launches Biochar Carbon Credits Through Puro.earth
Clean Maine Carbon's Groundbreaking Initiative Clean Maine Carbon (CMC) has taken a significant step forward in sustainable carbon removal by launching its first biochar CO2 Removal Certificates (CORCs). Teaming up with Flowcarbon as its carbon development partner, CMC's move marks a pivotal moment in the quest for innovative solutions to combat climate change. The Role...
Continue Reading